NCAM1 and rhabdomyosarcoma: Moreover, from the translational perspective, huN901-DM1 is currently being evaluated as monotherapy in children with various NCAM1-expressing solid tumors including: Wilms tumor, rhabdomyosarcoma, neuroblastoma, malignant peripheral nerve sheath tumor and synovial sarcoma.